Table 2: Sensitivity of core biopsy versus FNA for detection of 70 patients with Axillary node metastases.

Factor Core detected (%)FNA detected (%)Difference in sensitivities (core-FNA) Discordant value

Overall7061 (87.1)55 (78.6)8.6%140.18
Number of core passes
 1 pass1411 (78.6)
 >15650 (89.3)
Core needle size
 12 g98 (88.9)
 1 core pass87 (87.5)
 >1 core pass11 (100)
 14 g or 18 g6153 (86.9)
 1 core pass64 (66.7)
 >1 core pass5549 (89.1)
Number of FNA entries
 1 entry6046 (76.7)
 >1109 (90)
FNA needle size
 21 g5341 (77.4)
 1 FNA entry4635 (76.1)
 >1 FNA entry76 (85.7)
 25 g1714 (82.4)
 1 FNA entry1411 (78.6)
 >1 FNA entry33 (100)
Hilus
 Present5144 (86.3)36 (70.6)15.7%12
 Absent1917 (89.5)19 (100)−10.5%2
Cortex
 2 mm11 (100)0 (0)100.0%1
 2.1–4 mm138 (61.5)7 (53.8)7.7%3
 4.1–6 mm2018 (90)15 (75)15.0%5
 >6 mm3634 (94.4)33 (91.7)2.8%5
Shape
 Normal2116 (76.2)11 (52.4)23.8%5
 Focal bulge2019 (95)16 (80)15.0%5
 Round2322 (95.7)22 (95.7)0.0%2
 Ill-defined64 (66.7)6 (100)−33.3%2
Number of suspicious nodes
 13126 (83.9)23 (74.2)9.7%7
 21613 (81.3)11 (68.8)12.5%4
 31010 (100)9 (90)10.0%1
 4 or more1312 (92.3)12 (92.3)0.0%2
Tumor size by imaging
 5 mm–1 cm44 (100)2 (50)50.0%2
 >1 cm-2 cm1916 (84.2)14 (73.7)10.5%4
 >2 cm–5 cm3631 (86.1)31 (86.1)2.8%5
 >5 cm119 (81.8)8 (72.7)9.1%3
Chemotherapy status
 No chemotherapy2620 (76.9)17 (65.4)11.5%5
 Neoadjuvant 4037 (92.5)34 (85.0)7.5%9
 Other*44 (100)4 (100)0.0%0

*Other: 4 patients were both core and FNA positive but did not have axillary surgery.